Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Change in Accured Expenses: 2023-2024

Historic Change in Accured Expenses for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $22.1 million.

  • Zenas BioPharma's Change in Accured Expenses rose 537.50% to $102,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 27.42%. This contributed to the annual value of $22.1 million for FY2024, which is 720.15% up from last year.
  • According to the latest figures from FY2024, Zenas BioPharma's Change in Accured Expenses is $22.1 million, which was up 720.15% from -$3.6 million recorded in FY2023.
  • Zenas BioPharma's 5-year Change in Accured Expenses high stood at $22.1 million for FY2024, and its period low was -$3.6 million during FY2023.
  • Its 2-year average for Change in Accured Expenses is $9.3 million, with a median of $9.3 million in 2023.
  • Data for Zenas BioPharma's Change in Accured Expenses shows a peak YoY soared of 720.15% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Zenas BioPharma's Change in Accured Expenses stood at -$3.6 million in 2023, then skyrocketed by 720.15% to $22.1 million in 2024.